"Abstract
The post-infection of COVID-19 includes a myriad of neurologic symptoms including neurodegeneration. Protein aggregation in brain can be considered as one of the important reasons behind the neurodegeneration...
1. Introduction
In this study, we have investigated the interactions of SARS-CoV-2 S1 RBD to different amyloid forming proteins...We also examine the binding of S1 RBD to heparin and their complex to the different amyloidogenic proteins present in the brain.
4. Conclusion
... the findings reported here support the hypothesis that the SARS-CoV-2 spike protein can interact with heparin binding amyloid forming proteins. Our results indicate stable binding of the S1 protein to these aggregation-prone proteins which might initiates [sic] aggregation of brain protein and accelerate neurodegeneration. These findings might explain the possible neurological distresses associated with COVID-19."
© 2021 Elsevier Inc. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.